{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T16:45:37Z","timestamp":1790700337609,"version":"4.1.0"},"reference-count":170,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100005979","name":"Lustgarten Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005979","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000043","name":"American Association for Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000043","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006156","name":"Sidney Kimmel Foundation for Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006156","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009560","name":"American Gastroenterological Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009560","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["CA62924"],"award-info":[{"award-number":["CA62924"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01CA176828"],"award-info":[{"award-number":["R01CA176828"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K08 DK107781"],"award-info":[{"award-number":["K08 DK107781"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U01210170"],"award-info":[{"award-number":["U01210170"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001784","name":"Pancreatic Cancer Action Network","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001784","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gastrojournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gastroenterology"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1053\/j.gastro.2018.12.039","type":"journal-article","created":{"date-parts":[[2019,1,18]],"date-time":"2019-01-18T01:17:51Z","timestamp":1547774271000},"page":"2041-2055","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":89,"title":["Genetics of Familial and Sporadic Pancreatic Cancer"],"prefix":"10.1053","volume":"156","author":[{"given":"Laura D.","family":"Wood","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew B.","family":"Yurgelun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael G.","family":"Goggins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.gastro.2018.12.039_bib1","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.1158\/0008-5472.CAN-14-0155","article-title":"Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States","volume":"74","author":"Rahib","year":"2014","journal-title":"Cancer Res"},{"key":"10.1053\/j.gastro.2018.12.039_bib2","first-page":"1731","article-title":"Tumor-suppressive pathways in pancreatic carcinoma","volume":"57","author":"Rozenblum","year":"1997","journal-title":"Cancer Res"},{"key":"10.1053\/j.gastro.2018.12.039_bib3","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/0092-8674(88)90571-5","article-title":"Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes","volume":"53","author":"Almoguera","year":"1988","journal-title":"Cell"},{"key":"10.1053\/j.gastro.2018.12.039_bib4","first-page":"545","article-title":"K-ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization","volume":"143","author":"Hruban","year":"1993","journal-title":"Am J Pathol"},{"key":"10.1053\/j.gastro.2018.12.039_bib5","doi-asserted-by":"crossref","first-page":"7773","DOI":"10.1093\/nar\/16.16.7773","article-title":"KRAS codon 12 mutations occur very frequently in pancreatic adenocarcinomas","volume":"16","author":"Smit","year":"1988","journal-title":"Nucleic Acids Res"},{"key":"10.1053\/j.gastro.2018.12.039_bib6","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/ng0994-27","article-title":"Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma","volume":"8","author":"Caldas","year":"1994","journal-title":"Nat Genet"},{"key":"10.1053\/j.gastro.2018.12.039_bib7","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1016\/S0002-9440(10)61104-2","article-title":"Aberrant methylation of preproenkephalin and p16 genes in pancreatic intraepithelial neoplasia and pancreatic ductal adenocarcinoma","volume":"160","author":"Fukushima","year":"2002","journal-title":"Am J Pathol"},{"key":"10.1053\/j.gastro.2018.12.039_bib8","first-page":"1534","article-title":"Pancreatic adenocarcinomas frequently show p53 gene mutations","volume":"142","author":"Scarpa","year":"1993","journal-title":"Am J Pathol"},{"key":"10.1053\/j.gastro.2018.12.039_bib9","first-page":"1556","article-title":"K-ras and p53 gene mutations in pancreatic cancer: ductal and nonductal tumors progress through different genetic lesions","volume":"54","author":"Pellegata","year":"1994","journal-title":"Cancer Res"},{"key":"10.1053\/j.gastro.2018.12.039_bib10","first-page":"3025","article-title":"p53 mutations in pancreatic carcinoma and evidence of common involvement of homocopolymer tracts in DNA microdeletions","volume":"54","author":"Redston","year":"1994","journal-title":"Cancer Res"},{"key":"10.1053\/j.gastro.2018.12.039_bib11","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1126\/science.271.5247.350","article-title":"DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1","volume":"271","author":"Hahn","year":"1996","journal-title":"Science"},{"key":"10.1053\/j.gastro.2018.12.039_bib12","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1158\/0008-5472.CAN-17-2727","article-title":"Oncogenic Ras isoforms signaling specificity at the membrane","volume":"78","author":"Nussinov","year":"2018","journal-title":"Cancer Res"},{"key":"10.1053\/j.gastro.2018.12.039_bib13","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1158\/1541-7786.MCR-13-0350","article-title":"The molecular balancing act of p16(INK4a) in cancer and aging","volume":"12","author":"LaPak","year":"2014","journal-title":"Mol Cancer Res"},{"key":"10.1053\/j.gastro.2018.12.039_bib14","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/j.cell.2017.08.028","article-title":"Putting p53 in context","volume":"170","author":"Kastenhuber","year":"2017","journal-title":"Cell"},{"key":"10.1053\/j.gastro.2018.12.039_bib15","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.trecan.2016.11.008","article-title":"Targeting TGF-beta signaling in cancer","volume":"3","author":"Colak","year":"2017","journal-title":"Trends Cancer"},{"key":"10.1053\/j.gastro.2018.12.039_bib16","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"10.1053\/j.gastro.2018.12.039_bib17","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1126\/science.1164368","article-title":"Core signaling pathways in human pancreatic cancers revealed by global genomic analyses","volume":"321","author":"Jones","year":"2008","journal-title":"Science"},{"key":"10.1053\/j.gastro.2018.12.039_bib18","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nature11547","article-title":"Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes","volume":"491","author":"Biankin","year":"2012","journal-title":"Nature"},{"key":"10.1053\/j.gastro.2018.12.039_bib19","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nature14169","article-title":"Whole genomes redefine the mutational landscape of pancreatic cancer","volume":"518","author":"Waddell","year":"2015","journal-title":"Nature"},{"key":"10.1053\/j.gastro.2018.12.039_bib20","doi-asserted-by":"crossref","first-page":"7686","DOI":"10.1038\/ncomms8686","article-title":"Clinical implications of genomic alterations in the tumour and circulation of pancreatic cancer patients","volume":"6","author":"Sausen","year":"2015","journal-title":"Nat Commun"},{"key":"10.1053\/j.gastro.2018.12.039_bib21","doi-asserted-by":"crossref","first-page":"6744","DOI":"10.1038\/ncomms7744","article-title":"Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets","volume":"6","author":"Witkiewicz","year":"2015","journal-title":"Nat Commun"},{"key":"10.1053\/j.gastro.2018.12.039_bib22","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1097\/00000421-200110000-00016","article-title":"Overexpression of the HER-2\/neu oncogene in pancreatic adenocarcinoma","volume":"24","author":"Safran","year":"2001","journal-title":"Am J Clin Oncol"},{"key":"10.1053\/j.gastro.2018.12.039_bib23","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.ccell.2017.07.007","article-title":"Integrated genomic characterization of pancreatic ductal adenocarcinoma","volume":"32","author":"Raphael","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1053\/j.gastro.2018.12.039_bib24","first-page":"5329","article-title":"Genetic alterations of the transforming growth factor beta receptor genes in pancreatic and biliary adenocarcinomas","volume":"58","author":"Goggins","year":"1998","journal-title":"Cancer Res"},{"key":"10.1053\/j.gastro.2018.12.039_bib25","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1002\/ijc.28765","article-title":"Genome-wide DNA methylation patterns in pancreatic ductal adenocarcinoma reveal epigenetic deregulation of SLIT-ROBO, ITGA2 and MET signaling","volume":"135","author":"Nones","year":"2014","journal-title":"Int J Cancer"},{"key":"10.1053\/j.gastro.2018.12.039_bib26","doi-asserted-by":"crossref","first-page":"4341","DOI":"10.1158\/1078-0432.CCR-10-3431","article-title":"Genome-wide analysis of promoter methylation associated with gene expression profile in pancreatic adenocarcinoma","volume":"17","author":"Vincent","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.gastro.2018.12.039_bib27","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1002\/cncr.21977","article-title":"Aberrant methylation of Reprimo correlates with genetic instability and predicts poor prognosis in pancreatic ductal adenocarcinoma","volume":"107","author":"Sato","year":"2006","journal-title":"Cancer"},{"key":"10.1053\/j.gastro.2018.12.039_bib28","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1158\/1078-0432.CCR-07-0487","article-title":"Absence of E-cadherin expression distinguishes noncohesive from cohesive pancreatic cancer","volume":"14","author":"Winter","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.gastro.2018.12.039_bib29","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nature12477","article-title":"Signatures of mutational processes in human cancer","volume":"500","author":"Alexandrov","year":"2013","journal-title":"Nature"},{"key":"10.1053\/j.gastro.2018.12.039_bib30","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1001\/jamaoncol.2016.3916","article-title":"Association of distinct mutational signatures with correlates of increased immune activity in pancreatic ductal adenocarcinoma","volume":"3","author":"Connor","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1053\/j.gastro.2018.12.039_bib31","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/nature19823","article-title":"A\u00a0renewed model of pancreatic cancer evolution based on genomic rearrangement patterns","volume":"538","author":"Notta","year":"2016","journal-title":"Nature"},{"key":"10.1053\/j.gastro.2018.12.039_bib32","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1038\/nature09515","article-title":"Distant metastasis occurs late during the genetic evolution of pancreatic cancer","volume":"467","author":"Yachida","year":"2010","journal-title":"Nature"},{"key":"10.1053\/j.gastro.2018.12.039_bib33","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/ng.3764","article-title":"Limited heterogeneity of known driver gene mutations among the metastases of individual patients with pancreatic cancer","volume":"49","author":"Makohon-Moore","year":"2017","journal-title":"Nat Genet"},{"key":"10.1053\/j.gastro.2018.12.039_bib34","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1038\/ng.3398","article-title":"Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma","volume":"47","author":"Moffitt","year":"2015","journal-title":"Nature Genet"},{"key":"10.1053\/j.gastro.2018.12.039_bib35","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1038\/nm.2344","article-title":"Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy","volume":"17","author":"Collisson","year":"2011","journal-title":"Nat Med"},{"key":"10.1053\/j.gastro.2018.12.039_bib36","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nature16965","article-title":"Genomic analyses identify molecular subtypes of pancreatic cancer","volume":"531","author":"Bailey","year":"2016","journal-title":"Nature"},{"key":"10.1053\/j.gastro.2018.12.039_bib37","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1001\/jama.2009.1529","article-title":"Risk of pancreatic cancer in families with Lynch syndrome","volume":"302","author":"Kastrinos","year":"2009","journal-title":"JAMA"},{"key":"10.1053\/j.gastro.2018.12.039_bib38","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1158\/2159-8290.CD-11-0194","article-title":"ATM mutations in patients with hereditary pancreatic cancer","volume":"2","author":"Roberts","year":"2012","journal-title":"Cancer Discov"},{"key":"10.1053\/j.gastro.2018.12.039_bib39","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/mc.20855","article-title":"Genetic susceptibility to pancreatic cancer","volume":"51","author":"Klein","year":"2012","journal-title":"Mol Carcinog"},{"key":"10.1053\/j.gastro.2018.12.039_bib40","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1093\/jnci\/89.6.442","article-title":"Hereditary pancreatitis and the risk of pancreatic cancer. International Hereditary Pancreatitis Study Group","volume":"89","author":"Lowenfels","year":"1997","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1053\/j.gastro.2018.12.039_bib41","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/gim.2014.153","article-title":"BRCA1, BRCA2, PALB2, and CDKN2A mutations in familial pancreatic cancer: a PACGENE study","volume":"17","author":"Zhen","year":"2015","journal-title":"Genet Med"},{"key":"10.1053\/j.gastro.2018.12.039_bib42","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1126\/science.1171202","article-title":"Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene","volume":"324","author":"Jones","year":"2009","journal-title":"Science"},{"key":"10.1053\/j.gastro.2018.12.039_bib43","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1158\/2159-8290.CD-15-0402","article-title":"Whole genome sequencing defines the genetic heterogeneity of familial pancreatic cancer","volume":"6","author":"Roberts","year":"2016","journal-title":"Cancer Discov"},{"key":"10.1053\/j.gastro.2018.12.039_bib44","doi-asserted-by":"crossref","first-page":"201720588","DOI":"10.1073\/pnas.1720588115","article-title":"Mutations in the pancreatic secretory enzymes CPA1 and CPB1 are associated with pancreatic cancer","volume":"115","author":"Tamura","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1053\/j.gastro.2018.12.039_bib45","doi-asserted-by":"crossref","first-page":"3382","DOI":"10.1200\/JCO.2017.72.3502","article-title":"Deleterious germline mutations in patients with apparently sporadic pancreatic adenocarcinoma","volume":"35","author":"Shindo","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1053\/j.gastro.2018.12.039_bib46","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1001\/jama.2018.6228","article-title":"Association between inherited germline mutations in cancer predisposition genes and risk of pancreatic cancer","volume":"319","author":"Hu","year":"2018","journal-title":"JAMA"},{"key":"10.1053\/j.gastro.2018.12.039_bib47","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1093\/jnci\/djy024","article-title":"Prospective evaluation of germline alterations in patients with exocrine pancreatic neoplasms","volume":"110","author":"Lowery","year":"2018","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1053\/j.gastro.2018.12.039_bib48","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/ng0596-123","article-title":"BRCA2 germline mutations in male breast cancer cases and breast cancer families","volume":"13","author":"Couch","year":"1996","journal-title":"Nat Genet"},{"key":"10.1053\/j.gastro.2018.12.039_bib49","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/ng0596-126","article-title":"Recurrent BRCA2 6174delT mutations in Ashkenazi Jewish women affected by breast cancer","volume":"13","author":"Neuhausen","year":"1996","journal-title":"Nat Genet"},{"key":"10.1053\/j.gastro.2018.12.039_bib50","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1038\/ng1096-188","article-title":"The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jewish individuals is approximately 1%","volume":"14","author":"Oddoux","year":"1996","journal-title":"Nat Genet"},{"key":"10.1053\/j.gastro.2018.12.039_bib51","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1054\/bjoc.2000.1605","article-title":"The rate of the 6174delT founder Jewish mutation in BRCA2 in patients with non-colonic gastrointestinal tract tumours in Israel","volume":"84","author":"Figer","year":"2001","journal-title":"Br J Cancer"},{"key":"10.1053\/j.gastro.2018.12.039_bib52","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/ng0597-17","article-title":"Germline BRCA2 6174delT mutations in Ashkenazi Jewish pancreatic cancer patients","volume":"16","author":"Ozcelik","year":"1997","journal-title":"Nat Genet"},{"key":"10.1053\/j.gastro.2018.12.039_bib53","doi-asserted-by":"crossref","first-page":"4382","DOI":"10.1002\/cncr.29664","article-title":"Identification of germline genetic mutations in patients with pancreatic cancer","volume":"121","author":"Salo-Mullen","year":"2015","journal-title":"Cancer"},{"key":"10.1053\/j.gastro.2018.12.039_bib54","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1200\/JCO.2015.64.0730","article-title":"Benefit of surveillance for pancreatic cancer in high-risk individuals: outcome of long-term prospective follow-up studies from three European expert centers","volume":"34","author":"Vasen","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1053\/j.gastro.2018.12.039_bib55","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1053\/gast.2000.20228","article-title":"Very high risk of cancer in familial Peutz-Jeghers syndrome","volume":"119","author":"Giardiello","year":"2000","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2018.12.039_bib56","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1002\/1097-0215(20000915)87:6<809::AID-IJC8>3.0.CO;2-U","article-title":"Risk of developing pancreatic cancer in families with familial atypical multiple mole melanoma associated with a specific 19 deletion of p16 (p16-Leiden)","volume":"87","author":"Vasen","year":"2000","journal-title":"Int J Cancer"},{"key":"10.1053\/j.gastro.2018.12.039_bib57","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1136\/jmg.2004.028829","article-title":"Cancer risks in BRCA2 families: estimates for sites other than breast and ovary","volume":"42","author":"van Asperen","year":"2005","journal-title":"J\u00a0Med Genet"},{"key":"10.1053\/j.gastro.2018.12.039_bib58","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/ng1095-198","article-title":"The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals","volume":"11","author":"Struewing","year":"1995","journal-title":"Nat Genet"},{"key":"10.1053\/j.gastro.2018.12.039_bib59","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1200\/JCO.2008.18.5546","article-title":"BRCA germline mutations in Jewish patients with pancreatic adenocarcinoma","volume":"27","author":"Ferrone","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1053\/j.gastro.2018.12.039_bib60","doi-asserted-by":"crossref","DOI":"10.1200\/PO.17.00291","article-title":"Multigene hereditary cancer panels reveal high-risk pancreatic cancer susceptibility genes","author":"Hu","year":"2018","journal-title":"JCO Precis Oncol"},{"key":"10.1053\/j.gastro.2018.12.039_bib61","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa1400382","article-title":"Breast-cancer risk in families with mutations in PALB2","volume":"371","author":"Antoniou","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2018.12.039_bib62","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1093\/jnci\/94.18.1358","article-title":"Cancer incidence in BRCA1 mutation carriers","volume":"94","author":"Thompson","year":"2002","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1053\/j.gastro.2018.12.039_bib63","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1158\/1055-9965.EPI-12-0195","article-title":"Risk of pancreatic cancer in breast cancer families from the breast cancer family registry","volume":"22","author":"Mocci","year":"2013","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1053\/j.gastro.2018.12.039_bib64","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1093\/jnci\/djp020","article-title":"ABO blood group and the risk of pancreatic cancer","volume":"101","author":"Wolpin","year":"2009","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1053\/j.gastro.2018.12.039_bib65","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1158\/0008-5472.CAN-09-2993","article-title":"Pancreatic cancer risk and ABO blood group alleles: results from the pancreatic cancer cohort consortium","volume":"70","author":"Wolpin","year":"2010","journal-title":"Cancer Res"},{"key":"10.1053\/j.gastro.2018.12.039_bib66","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.1158\/1055-9965.EPI-10-0751","article-title":"Variant ABO blood group alleles, secretor status, and risk of pancreatic cancer: results from the pancreatic cancer cohort consortium","volume":"19","author":"Wolpin","year":"2010","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1053\/j.gastro.2018.12.039_bib67","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1038\/ng.429","article-title":"Genome-wide association study identifies variants in the ABO locus associated with susceptibility to pancreatic cancer","volume":"41","author":"Amundadottir","year":"2009","journal-title":"Nat Genet"},{"key":"10.1053\/j.gastro.2018.12.039_bib68","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1038\/ng.522","article-title":"A\u00a0genome-wide association study identifies pancreatic cancer susceptibility loci on chromosomes 13q22.1, 1q32.1 and 5p15.33","volume":"42","author":"Petersen","year":"2010","journal-title":"Nat Genet"},{"key":"10.1053\/j.gastro.2018.12.039_bib69","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1158\/1055-9965.EPI-15-1217","article-title":"Association of common susceptibility variants of pancreatic cancer in higher risk patients: a PACGENE study","volume":"25","author":"Childs","year":"2016","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1053\/j.gastro.2018.12.039_bib70","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1038\/ng.3052","article-title":"Genome-wide association study identifies multiple susceptibility loci for pancreatic cancer","volume":"46","author":"Wolpin","year":"2014","journal-title":"Nat Genet"},{"key":"10.1053\/j.gastro.2018.12.039_bib71","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1200\/JCO.2013.50.9257","article-title":"American Society of Clinical Oncology Expert Statement: collection and use of a cancer family history for oncology providers","volume":"32","author":"Lu","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1053\/j.gastro.2018.12.039_bib72","doi-asserted-by":"crossref","first-page":"3124","DOI":"10.1200\/JCO.2014.59.7401","article-title":"Germline BRCA mutations in a large clinic-based cohort of patients with pancreatic adenocarcinoma","volume":"33","author":"Holter","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1053\/j.gastro.2018.12.039_bib73","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1158\/1055-9965.EPI-15-0455","article-title":"Prevalence of pathogenic mutations in cancer predisposition genes among pancreatic cancer patients","volume":"25","author":"Hu","year":"2016","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1053\/j.gastro.2018.12.039_bib74","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1002\/cncr.28662","article-title":"BRCA1 and BRCA2 germline mutations are frequently demonstrated in both high-risk pancreatic cancer screening and pancreatic cancer cohorts","volume":"120","author":"Lucas","year":"2014","journal-title":"Cancer"},{"key":"10.1053\/j.gastro.2018.12.039_bib75","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1053\/j.gastro.2015.08.056","article-title":"Genetic diversity of pancreatic ductal adenocarcinoma and opportunities for precision medicine","volume":"150","author":"Knudsen","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2018.12.039_bib76","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1093\/jnci\/dju379","article-title":"Population testing for cancer predisposing BRCA1\/BRCA2 mutations in the Ashkenazi-Jewish community: a randomized controlled trial","volume":"107","author":"Manchanda","year":"2015","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1053\/j.gastro.2018.12.039_bib77","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1001\/jamaoncol.2015.0658","article-title":"Effect of oophorectomy on survival after breast cancer in BRCA1 and BRCA2 mutation carriers","volume":"1","author":"Metcalfe","year":"2015","journal-title":"JAMA Oncol"},{"key":"10.1053\/j.gastro.2018.12.039_bib78","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1053\/j.gastro.2012.01.005","article-title":"Frequent detection of pancreatic lesions in asymptomatic high-risk individuals","volume":"142","author":"Canto","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2018.12.039_bib79","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1200\/JCO.2014.58.1322","article-title":"Hereditary colorectal cancer syndromes: American Society of Clinical Oncology Clinical Practice Guideline endorsement of the familial risk-colorectal cancer: European Society for Medical Oncology Clinical Practice Guidelines","volume":"33","author":"Stoffel","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1053\/j.gastro.2018.12.039_bib80","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/s41467-018-02942-5","article-title":"Genome-wide meta-analysis identifies five new susceptibility loci for pancreatic cancer","volume":"9","author":"Klein","year":"2018","journal-title":"Nat Commun"},{"key":"10.1053\/j.gastro.2018.12.039_bib81","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1053\/j.gastro.2018.05.035","article-title":"Risk of neoplastic progression in high-risk individuals undergoing long-term surveillance for pancreatic cancer","volume":"155","author":"Canto","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2018.12.039_bib82","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1136\/gutjnl-2012-303108","article-title":"International consensus recommendations on the management of patients with increased risk for familial pancreatic cancer (The Cancer of the Pancreas Screening (CAPS) Consortium Summit)","volume":"62","author":"Canto","year":"2013","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2018.12.039_bib83","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s10689-016-9930-4","article-title":"Factors associated with cancer worries in individuals participating in annual pancreatic cancer surveillance","volume":"16","author":"Konings","year":"2017","journal-title":"Fam Cancer"},{"key":"10.1053\/j.gastro.2018.12.039_bib84","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1097\/PAS.0000000000000533","article-title":"A\u00a0revised classification system and recommendations from the baltimore consensus meeting for neoplastic precursor lesions in the pancreas","volume":"39","author":"Basturk","year":"2015","journal-title":"Am J Surg Pathol"},{"key":"10.1053\/j.gastro.2018.12.039_bib85","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1053\/j.gastro.2011.12.042","article-title":"Presence of somatic mutations in most early-stage pancreatic intraepithelial neoplasia","volume":"142","author":"Kanda","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2018.12.039_bib86","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1593\/neo.04445","article-title":"Frequency of K-ras mutations in pancreatic intraductal neoplasias associated with pancreatic ductal adenocarcinoma and chronic pancreatitis: a meta-analysis","volume":"7","author":"Lohr","year":"2005","journal-title":"Neoplasia"},{"key":"10.1053\/j.gastro.2018.12.039_bib87","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1053\/j.gastro.2013.07.049","article-title":"Genetic alterations associated with progression from pancreatic intraepithelial neoplasia to invasive pancreatic tumor","volume":"145","author":"Murphy","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2018.12.039_bib88","first-page":"4740","article-title":"Inactivation of the p16 (INK4A) tumor-suppressor gene in pancreatic duct lesions: loss of intranuclear expression","volume":"58","author":"Wilentz","year":"1998","journal-title":"Cancer Res"},{"key":"10.1053\/j.gastro.2018.12.039_bib89","first-page":"2002","article-title":"Loss of expression of Dpc4 in pancreatic intraepithelial neoplasia: evidence that DPC4 inactivation occurs late in neoplastic progression","volume":"60","author":"Wilentz","year":"2000","journal-title":"Cancer Res"},{"key":"10.1053\/j.gastro.2018.12.039_bib90","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1016\/S0002-9440(10)64123-5","article-title":"Allelic loss is often the first hit in the biallelic inactivation of the p53 and DPC4 genes during pancreatic carcinogenesis","volume":"158","author":"Luttges","year":"2001","journal-title":"Am J Pathol"},{"key":"10.1053\/j.gastro.2018.12.039_bib91","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1097\/PAS.0000000000001148","article-title":"Cancerization of the pancreatic ducts: demonstration of a common and under-recognized process using immunolabeling of paired duct lesions and invasive pancreatic ductal adenocarcinoma for p53 and Smad4 expression","volume":"42","author":"Hutchings","year":"2018","journal-title":"Am J Surg Pathol"},{"key":"10.1053\/j.gastro.2018.12.039_bib92","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1002\/path.4884","article-title":"Genetic analyses of isolated high-grade pancreatic intraepithelial neoplasia (HG-PanIN) reveal paucity of alterations in TP53 and SMAD4","volume":"242","author":"Hosoda","year":"2017","journal-title":"J\u00a0Pathol"},{"key":"10.1053\/j.gastro.2018.12.039_bib93","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0002-9440(10)64432-X","article-title":"Telomere shortening is nearly universal in pancreatic intraepithelial neoplasia","volume":"161","author":"van Heek","year":"2002","journal-title":"Am J Pathol"},{"key":"10.1053\/j.gastro.2018.12.039_bib94","doi-asserted-by":"crossref","first-page":"4303","DOI":"10.1158\/1078-0432.CCR-12-1075","article-title":"Genome-wide somatic copy number alterations in low-grade PanINs and IPMNs from individuals with a family history of pancreatic cancer","volume":"18","author":"Hong","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.gastro.2018.12.039_bib95","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1016\/j.ajpath.2018.03.012","article-title":"Genome-wide somatic copy number alterations and mutations in high-grade pancreatic intraepithelial neoplasia","volume":"188","author":"Hata","year":"2018","journal-title":"Am J Pathol"},{"key":"10.1053\/j.gastro.2018.12.039_bib96","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1097\/00000478-200407000-00001","article-title":"Pathologically and biologically distinct types of epithelium in intraductal papillary mucinous neoplasms: delineation of an \u201cintestinal\u201d pathway of carcinogenesis in the pancreas","volume":"28","author":"Adsay","year":"2004","journal-title":"Am J Surg Pathol"},{"key":"10.1053\/j.gastro.2018.12.039_bib97","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1002\/path.4344","article-title":"Targeted next-generation sequencing of cancer genes dissects the molecular profiles of intraductal papillary neoplasms of the pancreas","volume":"233","author":"Amato","year":"2014","journal-title":"J\u00a0Pathol"},{"key":"10.1053\/j.gastro.2018.12.039_bib98","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/S0002-9440(10)64589-0","article-title":"Dpc-4 protein is expressed in virtually all human intraductal papillary mucinous neoplasms of the pancreas: comparison with conventional ductal adenocarcinomas","volume":"157","author":"Iacobuzio-Donahue","year":"2000","journal-title":"Am J Pathol"},{"key":"10.1053\/j.gastro.2018.12.039_bib99","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1136\/gut.50.6.861","article-title":"Aberrant p16(INK4A) and DPC4\/Smad4 expression in intraductal papillary mucinous tumours of the pancreas is associated with invasive ductal adenocarcinoma","volume":"50","author":"Biankin","year":"2002","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2018.12.039_bib100","doi-asserted-by":"crossref","first-page":"92ra66","DOI":"10.1126\/scitranslmed.3002543","article-title":"Recurrent GNAS mutations define an unexpected pathway for pancreatic cyst development","volume":"3","author":"Wu","year":"2011","journal-title":"Sci Transl Med"},{"key":"10.1053\/j.gastro.2018.12.039_bib101","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/srep00161","article-title":"Whole-exome sequencing uncovers frequent GNAS mutations in intraductal papillary mucinous neoplasms of the pancreas","volume":"1","author":"Furukawa","year":"2011","journal-title":"Sci Rep"},{"key":"10.1053\/j.gastro.2018.12.039_bib102","doi-asserted-by":"crossref","first-page":"21188","DOI":"10.1073\/pnas.1118046108","article-title":"Whole-exome sequencing of neoplastic cysts of the pancreas reveals recurrent mutations in components of ubiquitin-dependent pathways","volume":"108","author":"Wu","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1053\/j.gastro.2018.12.039_bib103","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1038\/modpathol.2016.98","article-title":"The oncocytic subtype is genetically distinct from other pancreatic intraductal papillary mucinous neoplasm subtypes","volume":"29","author":"Basturk","year":"2016","journal-title":"Mod Pathol"},{"key":"10.1053\/j.gastro.2018.12.039_bib104","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1097\/PAS.0b013e31822769a0","article-title":"Somatic mutations in PIK3CA and activation of AKT in intraductal tubulopapillary neoplasms of the pancreas","volume":"35","author":"Yamaguchi","year":"2011","journal-title":"Am J Surg Pathol"},{"key":"10.1053\/j.gastro.2018.12.039_bib105","doi-asserted-by":"crossref","first-page":"3851","DOI":"10.1158\/1078-0432.CCR-06-0292","article-title":"PIK3CA mutations in intraductal papillary mucinous neoplasm\/carcinoma of the pancreas","volume":"12","author":"Schonleben","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.gastro.2018.12.039_bib106","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1097\/00000658-199910000-00006","article-title":"Sequential accumulation of K-ras mutations and p53 overexpression in the progression of pancreatic mucinous cystic neoplasms to malignancy","volume":"230","author":"Jimenez","year":"1999","journal-title":"Ann Surg"},{"key":"10.1053\/j.gastro.2018.12.039_bib107","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1097\/00000478-200011000-00011","article-title":"Dpc4 protein in mucinous cystic neoplasms of the pancreas: frequent loss of expression in invasive carcinomas suggests a role in genetic progression","volume":"24","author":"Iacobuzio-Donahue","year":"2000","journal-title":"Am J Surg Pathol"},{"key":"10.1053\/j.gastro.2018.12.039_bib108","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1097\/MPA.0000000000000805","article-title":"Genomic characterization of low- and high-grade pancreatic mucinous cystic neoplasms reveals recurrent KRAS alterations in \u201chigh-risk\u201d lesions","volume":"46","author":"Conner","year":"2017","journal-title":"Pancreas"},{"key":"10.1053\/j.gastro.2018.12.039_bib109","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1136\/gutjnl-2017-315062","article-title":"IPMNs with co-occurring invasive cancers: neighbours but not always relatives","volume":"67","author":"Felsenstein","year":"2018","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2018.12.039_bib110","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1002\/path.5194","article-title":"Single-cell sequencing defines genetic heterogeneity in pancreatic cancer precursor lesions","volume":"247","author":"Kuboki","year":"2019","journal-title":"J\u00a0Pathol"},{"key":"10.1053\/j.gastro.2018.12.039_bib111","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1097\/SLA.0000000000001817","article-title":"Targeted DNA sequencing reveals patterns of local progression in the pancreatic remnant following resection of intraductal papillary mucinous neoplasm (IPMN) of the pancreas","volume":"266","author":"Pea","year":"2017","journal-title":"Ann Surg"},{"key":"10.1053\/j.gastro.2018.12.039_bib112","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/s41586-018-0481-8","article-title":"Precancerous neoplastic cells can move through the pancreatic ductal system","volume":"561","author":"Makohon-Moore","year":"2018","journal-title":"Nature"},{"key":"10.1053\/j.gastro.2018.12.039_bib113","doi-asserted-by":"crossref","first-page":"224ra24","DOI":"10.1126\/scitranslmed.3007094","article-title":"Detection of circulating tumor DNA in early- and late-stage human malignancies","volume":"6","author":"Bettegowda","year":"2014","journal-title":"Sci Transl Med"},{"issue":"6378","key":"10.1053\/j.gastro.2018.12.039_bib114","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1126\/science.aar3247","article-title":"Detection and localization of surgically resectable cancers with a multi-analyte blood test","volume":"359","author":"Cohen","year":"2018","journal-title":"Science"},{"key":"10.1053\/j.gastro.2018.12.039_bib115","doi-asserted-by":"crossref","first-page":"10202","DOI":"10.1073\/pnas.1704961114","article-title":"Combined circulating tumor DNA and protein biomarker-based liquid biopsy for the earlier detection of pancreatic cancers","volume":"114","author":"Cohen","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1053\/j.gastro.2018.12.039_bib116","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1136\/gutjnl-2016-313586","article-title":"Preoperative next-generation sequencing of pancreatic cyst fluid is highly accurate in cyst classification and detection of advanced neoplasia","volume":"67","author":"Singhi","year":"2018","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2018.12.039_bib117","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1053\/j.gastro.2015.07.041","article-title":"A\u00a0combination of molecular markers and clinical features improve the classification of pancreatic cysts","volume":"149","author":"Springer","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2018.12.039_bib118","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1136\/gutjnl-2015-311166","article-title":"Digital next-generation sequencing identifies low-abundance mutations in pancreatic juice samples collected from the duodenum of patients with pancreatic cancer and intraductal papillary mucinous neoplasms","volume":"66","author":"Yu","year":"2017","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2018.12.039_bib119","doi-asserted-by":"crossref","first-page":"2963","DOI":"10.1158\/1078-0432.CCR-17-2463","article-title":"Pancreatic juice mutation concentrations can help predict the grade of dysplasia in patients undergoing pancreatic surveillance","volume":"24","author":"Suenaga","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.gastro.2018.12.039_bib120","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1136\/gutjnl-2012-302823","article-title":"Mutant GNAS detected in duodenal collections of secretin-stimulated pancreatic juice indicates the presence or emergence of pancreatic cysts","volume":"62","author":"Kanda","year":"2013","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2018.12.039_bib121","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.cgh.2014.11.028","article-title":"KRAS and guanine nucleotide-binding protein mutations in pancreatic juice collected from the duodenum of patients at high risk for neoplasia undergoing endoscopic ultrasound","volume":"13","author":"Eshleman","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2018.12.039_bib122","article-title":"Highly accurate identification of cystic precursor lesions of pancreatic cancer through targeted mass spectrometry: a phase IIc diagnostic study","author":"Jabbar","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1053\/j.gastro.2018.12.039_bib123","doi-asserted-by":"crossref","first-page":"3935","DOI":"10.1158\/1078-0432.CCR-16-2244","article-title":"Predicting the grade of dysplasia of pancreatic cystic neoplasms using cyst fluid DNA methylation markers","volume":"23","author":"Hata","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.gastro.2018.12.039_bib124","doi-asserted-by":"crossref","first-page":"5141","DOI":"10.1158\/1078-0432.CCR-16-0311","article-title":"Cyst fluid telomerase activity predicts the histologic grade of cystic neoplasms of the pancreas","volume":"22","author":"Hata","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.gastro.2018.12.039_bib125","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1200\/JCO.2006.07.9525","article-title":"Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group","volume":"25","author":"Moore","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1053\/j.gastro.2018.12.039_bib126","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2018.12.039_bib127","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine","volume":"369","author":"Von Hoff","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2018.12.039_bib128","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1080\/0284186X.2017.1288922","article-title":"Gemcitabine mono-therapy versus gemcitabine plus targeted therapy in advanced pancreatic cancer: a meta-analysis of randomized phase III trials","volume":"56","author":"Ottaiano","year":"2017","journal-title":"Acta Oncol"},{"key":"10.1053\/j.gastro.2018.12.039_bib129","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1093\/annonc\/mdv264","article-title":"A\u00a0phase II\/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer","volume":"26","author":"O\u2019Neil","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1053\/j.gastro.2018.12.039_bib130","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1093\/annonc\/mdv027","article-title":"A\u00a0phase 3 randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas: the GAMMA trial","volume":"26","author":"Fuchs","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1053\/j.gastro.2018.12.039_bib131","doi-asserted-by":"crossref","first-page":"3605","DOI":"10.1200\/JCO.2009.25.7550","article-title":"Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205","volume":"28","author":"Philip","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1053\/j.gastro.2018.12.039_bib132","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1093\/annonc\/mdv133","article-title":"A\u00a0randomized, placebo-controlled phase III trial of masitinib plus gemcitabine in the treatment of advanced pancreatic cancer","volume":"26","author":"Deplanque","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1053\/j.gastro.2018.12.039_bib133","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/S1470-2045(11)70004-3","article-title":"Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study","volume":"12","author":"Kindler","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.gastro.2018.12.039_bib134","doi-asserted-by":"crossref","first-page":"3617","DOI":"10.1200\/JCO.2010.28.1386","article-title":"Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303)","volume":"28","author":"Kindler","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1053\/j.gastro.2018.12.039_bib135","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.1016\/j.ejca.2013.04.002","article-title":"Randomised, placebo-controlled, double-blind, parallel-group phase III study evaluating aflibercept in patients receiving first-line treatment with gemcitabine for metastatic pancreatic cancer","volume":"49","author":"Rougier","year":"2013","journal-title":"Eur J Cancer"},{"key":"10.1053\/j.gastro.2018.12.039_bib136","doi-asserted-by":"crossref","first-page":"21613","DOI":"10.18632\/oncotarget.25085","article-title":"Targeted therapies in the management of locally advanced and metastatic pancreatic cancer: a systematic review","volume":"9","author":"Sheahan","year":"2018","journal-title":"Oncotarget"},{"key":"10.1053\/j.gastro.2018.12.039_bib137","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti-PD-L1 antibody in patients with advanced cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2018.12.039_bib138","first-page":"828","article-title":"Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma","volume":"33","author":"Royal","year":"2010","journal-title":"J\u00a0Immunother"},{"key":"10.1053\/j.gastro.2018.12.039_bib139","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.canlet.2015.12.020","article-title":"Current progress in immunotherapy for pancreatic cancer","volume":"381","author":"Foley","year":"2016","journal-title":"Cancer Lett"},{"key":"10.1053\/j.gastro.2018.12.039_bib140","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.aan6733","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Le","year":"2017","journal-title":"Science"},{"key":"10.1053\/j.gastro.2018.12.039_bib141","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1053\/j.gastro.2016.09.060","article-title":"Hypermutation in pancreatic cancer","volume":"152","author":"Humphris","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2018.12.039_bib142","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1158\/1078-0432.CCR-17-3099","article-title":"Evaluating mismatch repair deficiency in pancreatic adenocarcinoma: challenges and recommendations","volume":"24","author":"Hu","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.gastro.2018.12.039_bib143","doi-asserted-by":"crossref","first-page":"5018","DOI":"10.1158\/1078-0432.CCR-18-0531","article-title":"Molecular profiling of pancreatic cancer patients: initial results from the know your tumor initiative","volume":"24","author":"Pishvaian","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.gastro.2018.12.039_bib144","doi-asserted-by":"crossref","DOI":"10.1158\/2159-8290.CD-18-0036","article-title":"NRG1 fusions in KRAS wild-type pancreatic cancer","volume":"8","author":"Heining","year":"2018","journal-title":"Cancer Discov"},{"key":"10.1053\/j.gastro.2018.12.039_bib145","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1158\/2159-8290.CD-18-0275","article-title":"Real-time genomic characterization of advanced pancreatic cancer to enable precision medicine","volume":"8","author":"Aguirre","year":"2018","journal-title":"Cancer Discov"},{"key":"10.1053\/j.gastro.2018.12.039_bib146","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1158\/1078-0432.CCR-17-2994","article-title":"Genomics-driven precision medicine for advanced pancreatic cancer: early results from the COMPASS trial","volume":"24","author":"Aung","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.gastro.2018.12.039_bib147","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1200\/JCO.2015.62.6598","article-title":"Lapatinib in combination with capecitabine plus oxaliplatin in human epidermal growth factor receptor 2-positive advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma: TRIO-013\/LOGiC\u2014a randomized phase III trial","volume":"34","author":"Hecht","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1053\/j.gastro.2018.12.039_bib148","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1016\/S1470-2045(18)30481-9","article-title":"Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study","volume":"19","author":"Tabernero","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.gastro.2018.12.039_bib149","doi-asserted-by":"crossref","first-page":"5018","DOI":"10.1158\/1078-0432.CCR-18-0531","article-title":"Molecular profiling of patients with pancreatic cancer: initial results from the know your tumor initiative","volume":"24","author":"Pishvaian","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.gastro.2018.12.039_bib150","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1056\/NEJMoa1714448","article-title":"Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children","volume":"378","author":"Drilon","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2018.12.039_bib151","doi-asserted-by":"crossref","DOI":"10.1158\/2159-8290.CD-18-0349","article-title":"Organoid profiling identifies common responders to chemotherapy in\u00a0pancreatic cancer","volume":"8","author":"Tiriac","year":"2018","journal-title":"Cancer Discov"},{"key":"10.1053\/j.gastro.2018.12.039_bib152","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/s41436-018-0009-5","article-title":"Germline cancer susceptibility gene variants, somatic second hits, and survival outcomes in patients with resected pancreatic cancer","volume":"21","author":"Yurgelun","year":"2018","journal-title":"Genet Med"},{"key":"10.1053\/j.gastro.2018.12.039_bib153","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1002\/cncr.31628","article-title":"Prospective study of germline genetic testing in incident cases of pancreatic adenocarcinoma","volume":"124","author":"Brand","year":"2018","journal-title":"Cancer"},{"key":"10.1053\/j.gastro.2018.12.039_bib154","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1158\/2159-8290.CD-18-0275","article-title":"Real-time genomic characterization of advanced pancreatic cancer to enable precision medicine","volume":"8","author":"Aguirre","year":"2018","journal-title":"Cancer Discov"},{"key":"10.1053\/j.gastro.2018.12.039_bib155","doi-asserted-by":"crossref","first-page":"19817","DOI":"10.18632\/oncotarget.24865","article-title":"Association between homologous recombination repair gene mutations and response to oxaliplatin in pancreatic cancer","volume":"9","author":"Kondo","year":"2018","journal-title":"Oncotarget"},{"key":"10.1053\/j.gastro.2018.12.039_bib156","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1038\/bjc.2017.19","article-title":"Overall survival and clinical characteristics of BRCA mutation carriers with stage I\/II pancreatic cancer","volume":"116","author":"Golan","year":"2017","journal-title":"Br J Cancer"},{"key":"10.1053\/j.gastro.2018.12.039_bib157","doi-asserted-by":"crossref","DOI":"10.1200\/PO.17.00087","article-title":"Homologous recombination deficiency in patients with pancreatic ductal adenocarcinoma and response to chemotherapy","author":"Shahda","year":"2018","journal-title":"JCO Precis Oncol"},{"key":"10.1053\/j.gastro.2018.12.039_bib158","doi-asserted-by":"crossref","DOI":"10.1200\/PO.17.00152","article-title":"Retrospective survival analysis of patients with advanced pancreatic ductal adenocarcinoma and germline BRCA or PALB2 mutations","author":"Reiss","year":"2018","journal-title":"JCO Precis Oncol"},{"key":"10.1053\/j.gastro.2018.12.039_bib159","doi-asserted-by":"crossref","first-page":"44073","DOI":"10.18632\/oncotarget.17237","article-title":"Olaparib in combination with irinotecan, cisplatin, and mitomycin C in patients with advanced pancreatic cancer","volume":"8","author":"Yarchoan","year":"2017","journal-title":"Oncotarget"},{"key":"10.1053\/j.gastro.2018.12.039_bib160","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1002\/cncr.31218","article-title":"Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: germline BRCA mutation carriers and wild-type BRCA pancreatic ductal adenocarcinoma","volume":"124","author":"O\u2019Reilly","year":"2018","journal-title":"Cancer"},{"key":"10.1053\/j.gastro.2018.12.039_bib161","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1158\/2159-8290.CD-16-1250","article-title":"Phase I, dose-escalation, two-part trial of the PARP inhibitor talazoparib in patients with advanced germline BRCA1\/2 mutations and selected sporadic cancers","volume":"7","author":"de Bono","year":"2017","journal-title":"Cancer Discov"},{"key":"10.1053\/j.gastro.2018.12.039_bib162","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1200\/JCO.2014.56.2728","article-title":"Olaparib monotherapy in patients with advanced cancer and a germline BRCA1\/2 mutation","volume":"33","author":"Kaufman","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1053\/j.gastro.2018.12.039_bib163","doi-asserted-by":"crossref","DOI":"10.1200\/PO.17.00316","article-title":"Rucaparib monotherapy in patients with pancreatic cancer and a known deleterious BRCA mutation","author":"Shroff","year":"2018","journal-title":"JCO Precis Oncol"},{"key":"10.1053\/j.gastro.2018.12.039_bib164","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.ejca.2017.11.004","article-title":"Phase II trial of veliparib in patients with previously treated BRCA-mutated pancreas ductal adenocarcinoma","volume":"89","author":"Lowery","year":"2018","journal-title":"Eur J Cancer"},{"key":"10.1053\/j.gastro.2018.12.039_bib165","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1056\/NEJMoa1802905","article-title":"Talazoparib in patients with advanced breast cancer and a germline BRCA mutation","volume":"379","author":"Litton","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2018.12.039_bib166","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1056\/NEJMoa1706450","article-title":"Olaparib for metastatic breast cancer in patients with a germline BRCA mutation","volume":"377","author":"Robson","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2018.12.039_bib167","doi-asserted-by":"crossref","first-page":"4257","DOI":"10.1158\/1078-0432.CCR-15-0887","article-title":"FDA approval summary: olaparib monotherapy in patients with deleterious germline BRCA-mutated advanced ovarian cancer treated with three or more lines of chemotherapy","volume":"21","author":"Kim","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.gastro.2018.12.039_bib168","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1158\/2326-6066.CIR-15-0044","article-title":"CTLA-4 blockade synergizes therapeutically with PARP inhibition in BRCA1-deficient ovarian cancer","volume":"3","author":"Higuchi","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"10.1053\/j.gastro.2018.12.039_bib169","doi-asserted-by":"crossref","first-page":"3711","DOI":"10.1158\/1078-0432.CCR-16-3215","article-title":"PARP inhibitor upregulates PD-L1 expression and enhances cancer-associated immunosuppression","volume":"23","author":"Jiao","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.gastro.2018.12.039_bib170","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1200\/JCO.2016.72.1340","volume":"35","author":"Lee","year":"2017","journal-title":"J\u00a0Clin Oncol"}],"container-title":["Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0016508519300563?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0016508519300563?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T09:44:46Z","timestamp":1762163086000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0016508519300563"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":170,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["S0016508519300563"],"URL":"https:\/\/doi.org\/10.1053\/j.gastro.2018.12.039","relation":{},"ISSN":["0016-5085"],"issn-type":[{"value":"0016-5085","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Genetics of Familial and Sporadic Pancreatic Cancer","name":"articletitle","label":"Article Title"},{"value":"Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.gastro.2018.12.039","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 by the AGA Institute","name":"copyright","label":"Copyright"}]}}